BRIEF-Imunon Sharpens Focus On Its Promising Pivotal Phase 3 Ovarian Cancer Study

Reuters

Feb 05

Feb 5 (Reuters) - Imunon Inc IMNN.O:

IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY
IMUNON INC - STRATEGIC RESTRUCTURING TO CUT NON-ESSENTIAL EXPENSES
IMUNON INC: PHASE 3 STUDY ENROLLMENT REMAINS AHEAD OF SCHEDULE AND ADVANCES COMPANY TOWARD FUTURE BLA FILING
IMUNON INC: ANNOUNCES STRATEGIC REORGANIZATION THAT WILL ELIMINATE HEADCOUNT NOT ESSENTIAL TO PHASE 3 TRIAL
IMUNON INC - KHURSHEED ANWER TO RETIRE AS EVP AND CSO

Source text: ID:nGNX1cJ9pP

Further company coverage: IMNN.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2609303990"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609303990\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609303990?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 21:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609303990","market":"nz","top_or_hot":-1,"title":"BRIEF-Imunon Sharpens Focus On Its Promising Pivotal Phase 3 Ovarian Cancer Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Imunon Sharpens Focus On Its Promising Pivotal Phase 3 Ovarian Cancer Study</title></head><body><p><span>Feb 5 (Reuters)</span><span> - </span>Imunon Inc <span>IMNN.O</span>:</p><ul><li><p>IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY</p></li><li><p>IMUNON INC - STRATEGIC RESTRUCTURING TO CUT NON-ESSENTIAL EXPENSES</p></li><li><p>IMUNON INC: PHASE 3 STUDY ENROLLMENT REMAINS AHEAD OF SCHEDULE AND ADVANCES COMPANY TOWARD <a href=\"https://laohu8.com/S/FUTR.UK\">FUTURE</a> BLA FILING</p></li><li><p>IMUNON INC: ANNOUNCES STRATEGIC REORGANIZATION THAT WILL ELIMINATE HEADCOUNT NOT ESSENTIAL TO PHASE 3 TRIAL</p></li><li><p>IMUNON INC - KHURSHEED ANWER TO RETIRE AS EVP AND CSO</p></li></ul><p>Source text: <span>ID:nGNX1cJ9pP</span></p><p>Further company coverage: <span>IMNN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Imunon Sharpens Focus On Its Promising Pivotal Phase 3 Ovarian Cancer Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Imunon Sharpens Focus On Its Promising Pivotal Phase 3 Ovarian Cancer Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-05 21:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Imunon Sharpens Focus On Its Promising Pivotal Phase 3 Ovarian Cancer Study</title></head><body><p><span>Feb 5 (Reuters)</span><span> - </span>Imunon Inc <span>IMNN.O</span>:</p><ul><li><p>IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY</p></li><li><p>IMUNON INC - STRATEGIC RESTRUCTURING TO CUT NON-ESSENTIAL EXPENSES</p></li><li><p>IMUNON INC: PHASE 3 STUDY ENROLLMENT REMAINS AHEAD OF SCHEDULE AND ADVANCES COMPANY TOWARD <a href=\"https://laohu8.com/S/FUTR.UK\">FUTURE</a> BLA FILING</p></li><li><p>IMUNON INC: ANNOUNCES STRATEGIC REORGANIZATION THAT WILL ELIMINATE HEADCOUNT NOT ESSENTIAL TO PHASE 3 TRIAL</p></li><li><p>IMUNON INC - KHURSHEED ANWER TO RETIRE AS EVP AND CSO</p></li></ul><p>Source text: <span>ID:nGNX1cJ9pP</span></p><p>Further company coverage: <span>IMNN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMNN","symbol_name":"Imunon, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nFWN3Z11EQ:1","article_id":"2609303990","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609303990","pubTimestamp":1770298120,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Imunon Sharpens Focus On Its Promising Pivotal Phase 3 Ovarian Cancer StudyFeb 5 (Reuters) - Imunon Inc IMNN.O:IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDYIMUNON I","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMNN":"Imunon, Inc.","BK4139":"生物科技"},"translate_title":"简介-Imunon更加关注其有前途的关键3期卵巢癌研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMNN":0.9},"content_text":"BRIEF-Imunon Sharpens Focus On Its Promising Pivotal Phase 3 Ovarian Cancer StudyFeb 5 (Reuters) - Imunon Inc IMNN.O:IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDYIMUNON INC - STRATEGIC RESTRUCTURING TO CUT NON-ESSENTIAL EXPENSESIMUNON INC: PHASE 3 STUDY ENROLLMENT REMAINS AHEAD OF SCHEDULE AND ADVANCES COMPANY TOWARD FUTURE BLA FILINGIMUNON INC: ANNOUNCES STRATEGIC REORGANIZATION THAT WILL ELIMINATE HEADCOUNT NOT ESSENTIAL TO PHASE 3 TRIALIMUNON INC - KHURSHEED ANWER TO RETIRE AS EVP AND CSOSource text: ID:nGNX1cJ9pPFurther company coverage: IMNN.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}